Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Free Radic Biol Med ; 156: 190-199, 2020 08 20.
Artículo en Inglés | MEDLINE | ID: mdl-32653511

RESUMEN

Studies have shown that infection, excessive coagulation, cytokine storm, leukopenia, lymphopenia, hypoxemia and oxidative stress have also been observed in critically ill Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) patients in addition to the onset symptoms. There are still no approved drugs or vaccines. Dietary supplements could possibly improve the patient's recovery. Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), present an anti-inflammatory effect that could ameliorate some patients need for intensive care unit (ICU) admission. EPA and DHA replace arachidonic acid (ARA) in the phospholipid membranes. When oxidized by enzymes, EPA and DHA contribute to the synthesis of less inflammatory eicosanoids and specialized pro-resolving lipid mediators (SPMs), such as resolvins, maresins and protectins. This reduces inflammation. In contrast, some studies have reported that EPA and DHA can make cell membranes more susceptible to non-enzymatic oxidation mediated by reactive oxygen species, leading to the formation of potentially toxic oxidation products and increasing the oxidative stress. Although the inflammatory resolution improved by EPA and DHA could contribute to the recovery of patients infected with SARS-CoV-2, Omega-3 fatty acids supplementation cannot be recommended before randomized and controlled trials are carried out.


Asunto(s)
Infecciones por Coronavirus/dietoterapia , Síndrome de Liberación de Citoquinas/dietoterapia , Suplementos Dietéticos , Ácidos Docosahexaenoicos/administración & dosificación , Ácido Eicosapentaenoico/administración & dosificación , Leucopenia/dietoterapia , Pandemias , Neumonía Viral/dietoterapia , Antiinflamatorios no Esteroideos/administración & dosificación , Betacoronavirus/patogenicidad , COVID-19 , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/metabolismo , Infecciones por Coronavirus/virología , Síndrome de Liberación de Citoquinas/epidemiología , Síndrome de Liberación de Citoquinas/metabolismo , Síndrome de Liberación de Citoquinas/virología , Coagulación Intravascular Diseminada/dietoterapia , Coagulación Intravascular Diseminada/epidemiología , Coagulación Intravascular Diseminada/metabolismo , Coagulación Intravascular Diseminada/virología , Humanos , Hipoxia/dietoterapia , Hipoxia/epidemiología , Hipoxia/metabolismo , Hipoxia/virología , Leucopenia/epidemiología , Leucopenia/metabolismo , Leucopenia/virología , Estrés Oxidativo , Neumonía Viral/epidemiología , Neumonía Viral/metabolismo , Neumonía Viral/virología , Ensayos Clínicos Controlados Aleatorios como Asunto , Especies Reactivas de Oxígeno/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , SARS-CoV-2
2.
Neurochem Res ; 38(12): 2625-30, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24135880

RESUMEN

Tyrosinemia type II, also known as Richner-Hanhart syndrome, is an autosomal recessive inborn error of metabolism caused by a deficiency of hepatic cytosolic tyrosine aminotransferase, and is associated with neurologic and development difficulties in numerous patients. Considering that the mechanisms underlying the neurological dysfunction in hypertyrosinemic patients are poorly known and that studies demonstrated that high concentrations of tyrosine provoke oxidative stress in vitro and in vivo in the cerebral cortex of rats, in the present study we investigate the oxidative stress parameters (enzymatic antioxidant defenses, thiobarbituric acid-reactive substances and protein carbonyl content) in cerebellum, hippocampus and striatum of 30-old-day rats after acute administration of L-tyrosine. Our results demonstrated that the acute administration of L-tyrosine increased the thiobarbituric acid reactive species levels in hippocampus and the carbonyl levels in cerebellum, hippocampus and striatum. In addition, acute administration of L-tyrosine significantly decreased superoxide dismutase activity in cerebellum, hippocampus and striatum, while catalase was increased in striatum. In conclusion, the oxidative stress may contribute, along with other mechanisms, to the neurological dysfunction characteristic of hypertyrosinemia and the administration of antioxidants may be considered as a potential adjuvant therapy for tyrosinemia, especially type II.


Asunto(s)
Encéfalo/efectos de los fármacos , Catalasa/metabolismo , Estrés Oxidativo/efectos de los fármacos , Tirosina/administración & dosificación , Animales , Encéfalo/enzimología , Encéfalo/metabolismo , Masculino , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismo , Tirosina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA